Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing
- PMID: 25032987
- PMCID: PMC4679146
- DOI: 10.1038/gim.2014.85
Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing
Conflict of interest statement
DISCLOSURE
A.R.B. and S.D. report that Myriad Genetics is covering the cost of multiplex testing in an ongoing clinical study. The other author declares no conflict of interest.
References
-
- Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267–1270. - PubMed
-
- Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic information. Genet Med. 2009;11:570–574. - PubMed
-
- Bunnik EM, de Jong A, Nijsingh N, de Wert GM. The new genetics and informed consent: differentiating choice to preserve autonomy. Bioethics. 2013;27:348–355. - PubMed
-
- Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893–901. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
